Week Ahead: Earnings, Medical Conferences, & Catalysts

Research evidence excerpt

Week Ahead: Earnings, Medical Conferences, & Catalysts

USA | Biotechnology EquityJulyResearch20, 2026

Week Ahead: Earnings, Medical Conferences, &

Catalysts

AACR Drug Discovery & Development (July 21-24) is this wk; abstracts post 1st

day of conf. Titles for IASLC World Conference on Lung Cancer (WCLC; Sep

12-15) post next wk on July 31.

Med confs this wk

AACR Drug Discovery & Development (July 21-24): Abstracts post 1st day of conf•

Jacobio (oral): JAB-BX600, a first-in-class EGFR-directed antiboEdy drug conjugate •

delivering a novel KRAS G12D inhibitor

ADT Pharma (poster): ADT-1004: A mechanistically distinct pan-RAS inhibitor with the •

potential to escape resistance and mitigate on-target toxicities that limit efficacy and

safety of other RAS inhibitors

ADT Pharma (poster): 2ADT-030, a novel PDE10 inhibitor that blocks RAS and β- •

catenin signaling with robust and durable antitumor activity and potential to mitigate

resistance and on-target toxicities of monospecific RAS inhibitors

PRLD (poster): Precision degrader-antibody conjugates (pDACs) with a SMARCA2/4 •

dual payload as targeted therapeutics for acute myeloid leukemia

Med conf titles next wk

IASLC World Conference on Lung Cancer (WCLC; Sep 12-15): Abstract titles will be released•

July 31 @12PM ET

CT.gov updates

ARWR: SHASTA-3 (NCT06347003) stopped recruiting as of 7/14.•

DNTH: started to recruit at 11 new sites (180 sites recruiting in total) for CIDP ph.III•

(NCT06858579) as of 7/10

NUVB: new ph.III posted w/ safusidenib in grade 2 IDH1mut glioma (NCT07712757) as of 7/17•

NUVB: new ph.II posted w/ safusidenib in IDH1mut glioma that discontinued vorasidenib tx•

due to progressive disease (NCT07703436) as of 7/14

RIGL: new ph.IIII posted for pralsetinib DDI study in pts w/ advanced or metastatic solid•